Voyager医疗 VYGR 深 沪
交易中 12-29 10:18:48 美东时间
4.02
-0.060
-1.47%
华盛通- 最 高4.08
- 今 开4.05
- 成交量 3.23万股
- 最 低 4.02
- 昨 收 4.08
- 总市值 2.22亿
- 52周最高 6.27
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.645
- 委 比 78.46%
- 总股本 5533.64万
- 历史最高 31.91
- 量 比 0.98
- 振 幅 1.47%
- 历史最低 2.46
- 每 手 1
- 风险率 0.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline
Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, raising concerns for next-generation tau-targeting drug programs.
11-26 01:22
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
Voyager Therapeutics Q3 EPS $(0.47) Beats $(0.51) Estimate, Sales $13.365M Beat $7.858M Estimate
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.51) by 7.48 percent. This is a 193.75 percent decrease over losses of $(0.16) per share
11-10 21:16
Voyager Reports Third Quarter 2025 Financial and Operating Results
Voyager Therapeutics reported its third quarter 2025 financial and operating results, highlighting progress in its neurotherapeutic pipeline and financial stability. Key updates include ongoing dosing for the anti-tau antibody VY7523 in Alzheimer's disease, IND-enabling studies for VY1706 (tau silencing gene therapy) expected to initiate in 2026, and the introduction of its Voyager NeuroShuttle™ platform for nonviral delivery. The company also en...
11-10 13:01
Voyager Therapeutics Advances Alzheimer’s Study with VY7523
Voyager Therapeutics Inc. (($VYGR)) announced an update on their ongoing clinic...
10-28 05:21
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst
Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining a Buy rating and $30 price target.
09-16 02:00
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 price target.
09-15 19:11
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics announced its participation in several upcoming investor conferences to discuss its non-viral delivery platform for neurotherapeutics. The company will present at events including Citi's Biopharma Back to School Conference, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. We...
08-26 11:00
